

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**AU STAR**

**奥星**

**Austar Lifesciences Limited**

**奥星生命科技有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6118)**

## **POSITIVE PROFIT ALERT**

This announcement is made by Austar Lifesciences Limited (“**Company**” and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules).

The board (“**Board**”) of directors (“**Directors**”, each a “**Director**”) of the Company wishes to inform the shareholders of the Company and potential investors that, based on a preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2024 and the information currently available to the Board, it is expected that a profit attributable to the owners of the Company in the range of approximately RMB3 million to RMB6 million for the six months ended 30 June 2024 will be recorded, as compared with a loss attributable to the owners of the Company of approximately RMB40 million for the six months ended 30 June 2023.

The expected turnaround from loss to profit is mainly attributable to the following reasons:

- (1) the absence of a loss of approximately RMB63.9 million, of which approximately RMB32 million was attributable to the owners of the Company, as recorded for the six months ended 30 June 2023 from H+E Pharma GmbH and S-Tec GmbH, the then indirect non-wholly-owned subsidiaries of the Company; and
- (2) the saving of operating expenses of approximately RMB10 million mainly from the initiatives in the Group’s organizational optimization.

The Group is still in the process of finalising the interim results of the Group for the six months ended 30 June 2024. The information contained in this announcement is only based on the preliminary assessment by the management of the Company by information currently available to the Group, including the unaudited consolidated management accounts of the Group for the six months ended 30 June 2024, which has not been reviewed by the Company's auditors or the audit committee of the Board and may be subject to adjustments. Details of the Group's financial information and performance will be disclosed when the Group's interim results for the six months ended 30 June 2024 are announced, which is expected to be published in late August 2024.

**Shareholders of the Company and potential investors should exercise caution when dealing in the shares of the Company.**

On behalf of the Board  
**Austar Lifesciences Limited**  
**Ho Kwok Keung, Mars**  
*Chairman and Chief Executive Officer*

Hong Kong, 30 July 2024

*As at the date of this announcement, the Board comprises four executive Directors, namely Mr. Ho Kwok Keung, Mars, Mr. Ho Kin Hung, Mr. Chen Yuewu and Madam Zhou Ning; one non-executive Director, namely Madam Ji Lingling; and three independent non-executive Directors, namely Mr. Cheung Lap Kei, Madam Chiu Hoi Shan and Mr. Leung Oi Kin.*